The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity of lurbinectedin (PM01183) as single agent and in combination in patients with endometrial cancer.
 
Martin David Forster
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Lilly; Merck; Novartis; Pfizer
Travel, Accommodations, Expenses - Boehringer Ingelheim; Lilly; Merck; MSD; Pfizer; Roche
 
Victor Moreno
No Relationships to Disclose
 
Valentina Boni
No Relationships to Disclose
 
Eva Guerra
No Relationships to Disclose
 
Andres Poveda
Consulting or Advisory Role - AstraZeneca; Immunogen; Novartis; Roche
Travel, Accommodations, Expenses - PharmaMar
 
Rebecca Kristeleit
No Relationships to Disclose
 
Carmen Maria Kahatt
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Pilar Lardelli
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Jose Antonio Lopez Vilarino
Employment - PharmaMar
 
Nazly M Cuevas
Employment - PharmaMar
 
Arturo Soto-Matos
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Emiliano Calvo
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Lilly/ImClone; Nanobiotix; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Janssen Oncology; Lilly; Merck; Millennium; Nektar; Novartis; OncoMed; Pfizer; PharmaMar; PsiOxus Therapeutics; Puma Biotechnology; Roche/Genentech; Sanofi; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Lilly; Novartis; PsiOxus Therapeutics
Other Relationship - Pierre Fabre